In sync with the recent vaccine trends, South Korea-based contract development and manufacturing organization (CDMO), Samsung Biologics is all set to add mRNA vaccine drug substance manufacturing suite to expand its portfolio of services. In conversation with BioSpectrum Asia, James Choi, Senior VP, Chief Information and Marketing Officer, and Head of Investor Relations, Samsung Biologics, South Korea, talks in detail about the company’s growth plans.
All rights are reserved by the media that published this article.
In sync with the recent vaccine trends, South Korea-based contract development and manufacturing organization (CDMO), Samsung Biologics is all set to add mRNA vaccine drug substance manufacturing suite to expand its portfolio of services. In conversation with BioSpectrum Asia, James Choi, Senior VP, Chief Information and Marketing Officer, and Head of Investor Relations, Samsung Biologics, South Korea, talks in detail about the company’s growth plans.
All rights are reserved by the media that published this article.